Table 3.

Unadjusted models for DFS and OS¹

Gene/Clinical	Comparison	Unadjusted DFS		Unadjusted OS
		HR (95% CI)	Wald P-value	HR (95% CI)	Wald P-value
CYP2B6	Any variant vs. All WT	1.10 (0.83, 1.46)	0.51	1.12 (0.83, 1.52)	0.46
CYP2C9	Any variant vs. All WT	0.97 (0.72, 1.29)	0.82	1.01 (0.75, 1.37)	0.94
CYP2D6	G/A vs. A/A	1.07 (0.57, 2.03)	0.83	1.30 (0.64, 2.62)	0.46
	G/G vs. A/A	0.89 (0.48, 1.65)	0.72	1.01 (0.51, 1.99)	0.98
CYP3A4	*1B/*1A vs. *1A/*1A	1.70 (1.10, 2.63)	0.02	1.21 (0.74, 1.96)	0.45
	*1B/*1B vs *1A/*1A	1.96 (0.96, 3.98)	0.07	1.64 (0.77, 3.50)	0.20
CYP3A5	*3/*1 vs. *1/*1	0.76 (0.36, 1.59)	0.47	1.18 (0.49, 2.84)	0.72
	*3/*3 vs. *1/*1	0.74 (0.38, 1.45)	0.38	1.18 (0.52, 2.67)	0.69
CYP3A5	*6/*1 vs. *1/*1	2.71 (1.01, 7.32)	0.05	2.47 (0.92, 6.66)	0.07
GSTM1	Null vs. Non-null	0.71 (0.54, 0.93)	0.02	0.71 (0.53, 0.94)	0.02
GSTT1	Null vs. Non-null	1.41 (1.00, 1.97)	0.05	1.31 (0.91, 1.88)	0.14
GSTP1	Any Var vs. All WT	1.03 (0.79, 1.36)	0.81	1.18 (0.88, 1.57)	0.27
CYP-GST genotype groups	Unfavorable vs. Intermediate or Favorable	1.29 (0.97-1.72)	0.08	1.32 (0.98-1.79)	0.07
Lymph node	Continuous	1.02 (1.00, 1.04)	0.06	1.02 (1.00, 1.04)	0.10
Tumor size	Continuous	1.00 (1.00, 1.01)	0.36	1.00 (1.00, 1.01)	0.13
Age	Continuous	0.99 (0.97, 1.00)	0.10	0.99 (0.97, 1.01)	0.28
ER	Pos vs. Neg	0.79 (0.60, 1.04)	0.10	0.78 (0.58, 1.04)	0.10
PR	Pos vs. Neg	0.82 (0.62, 1.07)	0.15	0.88 (0.66, 1.17)	0.37
Race	Black vs. White	1.44 (0.84, 2.48)	0.19	1.41 (0.80, 2.49)	0.23
	Other vs. White	1.49 (0.83, 2.68)	0.18	1.20 (0.64, 2.28)	0.57
Arm	CAF+HDC vs. CAF	0.79 (0.60, 1.03)	0.08	0.93 (0.70, 1.23)	0.59

¹Cox Regression

CAF: cyclophosphamide, doxorubicin, fluorouracil; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; HR: hazard ratio; PR: progesterone receptor; OS: overall survival